163 related articles for article (PubMed ID: 32493288)
1. Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: a multicenter analysis in Thailand.
Ngamphaiboon N; Dechaphunkul A; Setakornnukul J; Dechaphunkul T; Jiratrachu R; Suktitipat B; Jiarpinitnun C; Pattaranutaporn P; Danchaivijitr P
BMC Cancer; 2020 Jun; 20(1):518. PubMed ID: 32493288
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
[TBL] [Abstract][Full Text] [Related]
3. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.
Liu DH; Zhou XY; Pan YG; Chen S; Ye ZH; Chen GD
Cancer Med; 2020 Feb; 9(4):1287-1297. PubMed ID: 31859464
[TBL] [Abstract][Full Text] [Related]
4. Raltitrexed versus 5-fluorouracil with cisplatin and concurrent radiotherapy for locally advanced nasopharyngeal carcinoma: An open labeled, randomized, controlled, and multicenter clinical trial.
Yan P; Yin H; Guo W; Sun X; Li F; Huang S; Bian X; Wang F; Zhang F; Wang B; Zhou H; Zhou C; Yin L; Jiang X; Jiang N; Wu J; Liu J; Song D; He X
Cancer Med; 2020 Sep; 9(17):6166-6172. PubMed ID: 32657029
[TBL] [Abstract][Full Text] [Related]
5. Long term complications and prognostic factors in locally advanced nasopharyngeal carcinoma treated with docetaxel, cisplatin, 5-fluorouracil induction chemotherapy followed by concurrent chemoradiotherapy: A retrospective cohort study.
Shim HJ; Kim HJ; Hwang JE; Bae WK; Chung IJ; Lee DH; Mi YT; Lee JK; Lim SC; Chung JW; Cho SH
Medicine (Baltimore); 2020 Dec; 99(49):e23173. PubMed ID: 33285692
[TBL] [Abstract][Full Text] [Related]
6. Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma.
Li XY; Chen QY; Sun XS; Liu SL; Yan JJ; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Wen YF; Guo L; Mo HY; Chen MY; Sun Y; Ma J; Tang LQ; Mai HQ
Eur J Cancer; 2019 Mar; 110():24-31. PubMed ID: 30739837
[TBL] [Abstract][Full Text] [Related]
7. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW
Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
[TBL] [Abstract][Full Text] [Related]
9. A comparison of cisplatin cumulative dose and cisplatin schedule in patients treated with concurrent chemo-radiotherapy in nasopharyngeal carcinoma.
Gundog M; Basaran H; Bozkurt O; Eroglu C
Braz J Otorhinolaryngol; 2020; 86(6):676-686. PubMed ID: 31164277
[TBL] [Abstract][Full Text] [Related]
10. Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma.
Zong JF; Liang QD; Lu QJ; Liu YH; Xu HC; Chen BJ; Guo QJ; Xu Y; Hu CR; Pan JJ; Lin SJ
BMC Cancer; 2021 Nov; 21(1):1274. PubMed ID: 34823489
[TBL] [Abstract][Full Text] [Related]
11. Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma.
Wang K; Dong J; He S; Wang X; Jiang C; Hu P; Guo J; Cai X; Wang X
BMC Cancer; 2019 May; 19(1):482. PubMed ID: 31117967
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity.
Lee AWM; Tung SY; Ng WT; Lee V; Ngan RKC; Choi HCW; Chan LLK; Siu LL; Ng AWY; Leung TW; Yiu HHY; O'Sullivan B; Chappell R
Cancer; 2017 Nov; 123(21):4147-4157. PubMed ID: 28662313
[TBL] [Abstract][Full Text] [Related]
13. Survival without adjuvant chemotherapy for selected patients with stage II and III nasopharyngeal carcinoma after concurrent chemoradiotherapy alone.
Wu JS; Tsai YC; Jian JJ; Chen HH; Horng CF; Cheng SH
Head Neck; 2018 Sep; 40(9):2070-2077. PubMed ID: 29756398
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced nasopharyngeal cancer using low- or high-dose concurrent chemoradiotherapy with intensity-modulated radiotherapy: A propensity score-matched, nationwide, population-based cohort study.
Chen TM; Lin KC; Yuan KS; Chang CL; Chow JM; Wu SY
Radiother Oncol; 2018 Oct; 129(1):23-29. PubMed ID: 29277447
[TBL] [Abstract][Full Text] [Related]
15. The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy.
Guo SS; Tang LQ; Zhang L; Chen QY; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
BMC Cancer; 2015 Dec; 15():977. PubMed ID: 26675209
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
Loong HH; Ma BB; Leung SF; Mo F; Hui EP; Kam MK; Chan SL; Yu BK; Chan AT
Radiother Oncol; 2012 Sep; 104(3):300-4. PubMed ID: 22300609
[TBL] [Abstract][Full Text] [Related]
17. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China.
Chen Y; Sun Y; Liang SB; Zong JF; Li WF; Chen M; Chen L; Mao YP; Tang LL; Guo Y; Lin AH; Liu MZ; Ma J
Cancer; 2013 Jun; 119(12):2230-8. PubMed ID: 23576020
[TBL] [Abstract][Full Text] [Related]
18. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response.
Liu SL; Sun XS; Yan JJ; Chen QY; Lin HX; Wen YF; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Li XY; Lin C; Du YY; Yang ZC; Xiao BB; Yang JH; Tang LQ; Guo L; Mai HQ
Radiother Oncol; 2019 Aug; 137():83-94. PubMed ID: 31078941
[TBL] [Abstract][Full Text] [Related]
19. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
[TBL] [Abstract][Full Text] [Related]
20. Locoregional Control and Mild Late Toxicity After Reducing Target Volumes and Radiation Doses in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy: 10-Year Results of a Phase 2 Study.
Zhao C; Miao JJ; Hua YJ; Wang L; Han F; Lu LX; Xiao WW; Wu HJ; Zhu MY; Huang SM; Lin CG; Deng XW; Xie CH
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):836-844. PubMed ID: 30954521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
